<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085120</url>
  </required_header>
  <id_info>
    <org_study_id>IEC-402/07.06.2019, RP-34/2019</org_study_id>
    <nct_id>NCT04085120</nct_id>
  </id_info>
  <brief_title>Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain</brief_title>
  <official_title>Comparison Between Ropivacaine/Dexamethasone and 10% Lignocaine Injection in Distal Glossopharyngeal Nerve Block for Intractable Cancer Pain- A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>All India Institute of Medical Sciences, New Delhi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>All India Institute of Medical Sciences, New Delhi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the efficacy and safety of Ropivacaine/dexamethasone vs 10% lignocaine
      injection in distal glossopharyngeal nerve block for intractable cancer pain
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction on the basis of the Numeric rating scale (NRS).</measure>
    <time_frame>4 weeks</time_frame>
    <description>Pain reduction on the basis of the Numeric rating scale (NRS). From 0 to 10 (No pain to highest pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)- short form</measure>
    <time_frame>4 weeks</time_frame>
    <description>BPI scores will be used to assess the change in pain before and after treatment. (Likert scale of 0 to 10, where 0 is none to 10 is maximum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Quality of Life-BREF</measure>
    <time_frame>4 weeks</time_frame>
    <description>WHO Quality of Life-BREF scores will be used to assess change in quality of life before and after treatment. (Likert scale of 0 to 5, where 0 is no interference to quality of life and 5 is maximum).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>4 weeeks</time_frame>
    <description>Number of Participants With Treatment Success at the End of Therapy as Measured by the Patient Global Impression of Change (PGIC). A treatment success is defined as Much or Very Much Improved at the Week 4. The PGIC is a 7-point Likert Scale, ranging from very much worse to very much improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGIC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of Participants With Treatment Success at the End of Therapy Based on Clinical Global Impression of Change (CGIC) . A treatment success is defined as Much or Very Much Improved at the Week 4. The PGIC is a 7-point Likert Scale, ranging from very much worse to very much improve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic requirement and rescue analgesic requirement</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number and dose of drugs before and after treatment will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer, Oropharynx</condition>
  <condition>Pain, Intractable</condition>
  <condition>Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine/dexamethasone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3ml of 0.75% ropivacaine and 1ml of 4mg/l dexamethasone will be injected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10% lignocaine injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 ml of 10% lignocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>0.75 % Ropivacaine/ 4mg/mL dexamethasone injection</intervention_name>
    <description>Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection</description>
    <arm_group_label>Ropivacaine/dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>10% lignocaine injection</intervention_name>
    <description>Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection</description>
    <arm_group_label>10% lignocaine injection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with proven carcinoma of the oropharynx and supraglottic larynx with
             estimated survival of 3 months or more.

          -  Pain lasting for at least 2 weeks with an average intensity of 5 or more on an
             11-point numeric rating scale (NRS) refractory to a combination strong opioids and
             NSAIDS

        Exclusion Criteria:

          1. Local infection or skin ulceration at the puncture site

          2. Local anaesthetic allergy

          3. Psychiatric illness that affected cooperation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dinesh Manoharan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dinesh Manoharan, MD</last_name>
    <phone>918447857079</phone>
    <email>dineshkimi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DINESH MANOHARAN</last_name>
      <phone>8447857079</phone>
      <email>dineshkimi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>dinesh manoharan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>September 8, 2019</last_update_submitted>
  <last_update_submitted_qc>September 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>All India Institute of Medical Sciences, New Delhi</investigator_affiliation>
    <investigator_full_name>Dr.Dinesh Manoharan</investigator_full_name>
    <investigator_title>Senior Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

